<DOC>
	<DOCNO>NCT00128271</DOCNO>
	<brief_summary>The purpose study determine safety tolerability bavituximab administer via vein single infusion examine bavituximab behave body affect amount hepatitis C virus individual chronic infection .</brief_summary>
	<brief_title>Study Bavituximab Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) infection world wide public health concern common chronic bloodborne infection United States lead indication liver transplantation . Laboratory animal study demonstrate bavituximab bind virus virally infected cell prolongs survival infect animal . This study examine safety tolerability bavituximab administer patient chronic HCV infection respond relapse treatment pegylated interferon plus ribavirin combination therapy . Groups patient treat escalate dos follow 12 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>At least 18 year age Chronic hepatitis C infection base history detectable serum HCV RNA Documented failure respond relapse treatment pegylated interferon ribavirin combination therapy Adequate hematologic function ( absolute neutrophil count [ ANC ] great equal 1,500 cells/uL , hemoglobin [ Hgb ] great equal 12 g/dL female great equal 13 g/dL male , platelet count great equal 100,000/uL less equal 500,000/uL ) Adequate renal function ( serum creatinine less equal 1.5 mg/dL calculate creatinine clearance great 60 mL/min ) Normal coagulation profile ( PT/INR aPTT within institutional normal limit ) Ddimer within institutional limit Female patient childbearing potential must negative serum pregnancy test prestudy patient reproductive potential must willing use approve form barrier method contraception Prior exposure chimeric antibody Any cause liver disease chronic hepatitis C , autoimmune alcoholic liver disease Decompensated clinical liver disease cirrhosis Any evidence clinically significant bleed Known history bleed diathesis coagulopathy Any history thromboembolic event include central venous catheterrelated thrombosis Any evidence history hypercoagulable state ( eg , elevate ddimer shorten aPTT ) Concurrent therapy oral parenteral anticoagulant Concurrent hormone therapy ( ie , estrogen contraceptive , hormone replacement , antiestrogen ) Antiviral therapy within 90 day day 0 Investigational therapy within 4 week day 0 Major surgery within 4 week day 0 Uncontrolled intercurrent disease Any history angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack A history condition require antiplatelet therapy exception general cardiovascular prophylaxis aspirin A history condition require treatment ( past current ) coumarintype agent Cardiac arrhythmia require medical therapy Serious nonhealing wound Requirement chronic daily treatment NSAIDs , antiplatelet drug ( eg , phosphodiesterase inhibitor , adenosine diphosphate receptor antagonist ) , steroids A disease concurrent therapy know cause significant alteration immunologic function Known HIV active hepatitis B virus ( HBV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>HCV</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>phase 1</keyword>
</DOC>